IBKS No2 SPAC (204840) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.088x

Based on the latest financial reports, IBKS No2 SPAC (204840) has a cash flow conversion efficiency ratio of -0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.73 Billion ≈ $-1.17 Million USD) by net assets (₩19.80 Billion ≈ $13.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View IBKS No2 SPAC (204840) stock price for real-time trading data and today's change.

IBKS No2 SPAC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how IBKS No2 SPAC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see IBKS No2 SPAC stock valuation for the company's overall valuation and market capitalisation.

IBKS No2 SPAC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of IBKS No2 SPAC ranked by their cash flow conversion efficiency. Also see IBKS No2 SPAC (204840) total assets for a full breakdown of the balance sheet.

Company	Cash Flow Conversion Efficiency
Dae Won Chem KO:024890	-0.022x
Anson Resources Limited F:9MY	-0.046x
Full Wang International Development Co Ltd TWO:6219	-0.287x
Rama Phosphates Limited NSE:RAMAPHO	0.011x
Tinka Resources Limited V:TK	-0.006x
RYTHM, Inc. NASDAQ:RYM	0.248x
Dae Young Pkg KO:014160	-0.015x
Hilbert Group AB Series B ST:HILB-B	-1.225x

Annual Cash Flow Conversion Efficiency for IBKS No2 SPAC (2015–2025)

The table below shows the annual cash flow conversion efficiency of IBKS No2 SPAC from 2015 to 2025. Review 204840 FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩19.92 Billion ≈ $13.50 Million	₩-1.12 Billion ≈ $-761.78K	-0.056x	+76.12%
2024-12-31	₩19.67 Billion ≈ $13.33 Million	₩-4.65 Billion ≈ $-3.15 Million	-0.236x	+22.80%
2023-12-31	₩12.28 Billion ≈ $8.32 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.306x	-288.18%
2022-12-31	₩16.09 Billion ≈ $10.90 Million	₩-1.27 Billion ≈ $-859.85K	-0.079x	+41.51%
2021-12-31	₩16.85 Billion ≈ $11.42 Million	₩-2.27 Billion ≈ $-1.54 Million	-0.135x	+27.62%
2020-12-31	₩14.31 Billion ≈ $9.70 Million	₩-2.67 Billion ≈ $-1.81 Million	-0.186x	+58.96%
2019-12-31	₩2.36 Billion ≈ $1.60 Million	₩-1.07 Billion ≈ $-726.36K	-0.454x	+6.69%
2018-12-31	₩7.82 Billion ≈ $5.30 Million	₩-3.80 Billion ≈ $-2.58 Million	-0.486x	+24.43%
2017-12-31	₩5.94 Billion ≈ $4.02 Million	₩-3.82 Billion ≈ $-2.59 Million	-0.644x	-38.10%
2016-12-31	₩8.57 Billion ≈ $5.81 Million	₩-3.99 Billion ≈ $-2.71 Million	-0.466x	-161.72%
2015-12-31	₩3.18 Billion ≈ $2.16 Million	₩2.40 Billion ≈ $1.63 Million	0.755x	--

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$48.40 Million

₩71.42 Billion KRW

Market Cap Rank

#22144 Global

#1375 in Korea

Share Price

₩4605.00

Change (1 day)

+0.77%

52-Week Range

₩780.00 - ₩4605.00

All Time High

₩8655.23